Table 2.

Patients’ clinical characteristics in relation to the FSH-R polymorphic variant at position 307 in patients with PCOS (n = 40) and in normo-ovulatory women with a normally appearing ovary at US (n = 66)

		ALA/ALA N = 34	ALA/THR N = 48	THR/THR N = 24
Age (years)	PCOS	33.3 ± 2.5	32.7 ± 3.7	32 ± 1.6
	Normal	33.5 ± 3.0	33.3 ± 2.7	32.8 ± 2.6
Body Mass Index (BMI)	PCOS	23 ± 4.1	23.6 ± 6.8	25.1 ± 4.5
	Normal	21.7 ± 2.7	23.3 ± 2.9	20.8 ± 2.3
Intercycle length (days)	PCOS	34.3 ± 6.0	38.3 ± 2.4	37.2 ± 13.1
	Normal	28 ± 1.3	28.1 ± 1.6	27.7 ± 0.7
FSH level in cycle day 3 (IU/L)	PCOS	5.8 ± 1.2	5.6 ± 2.4	6.3 ± 1.7
	Normal	8.4 ± 4.1	6.6 ± 1.8	7.3 ± 1.7
Basal antral follicle count (AFC)	PCOS	33 ± 6.0	29.3 ± 2.8	25.5 ± 5.5
	Normal	11.5 ± 1.5	13.4 ± 1.6	11.5 ± 1.9
Partner with abnormal semen (%)	PCOS	50 (3/6)	46.1 (12/26)	50 (4/8)
	Normal	50 (14/28)	54.5 (12/22)	50 (8/16)

No significant differences were detected for any of the studied variables when FSH-R polymorphic variants were compared.